Diamond rotors for clearer molecular images of Alzheimer’s proteins
Diamond Rotors
Building and using tiny diamond spinning rotors to get clearer molecular pictures of amyloid-beta proteins linked to Alzheimer’s disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11368528 on NIH RePORTER |
What this research studies
Researchers are developing tiny, laser-machined rotors made from single-crystal diamond that spin samples at much higher speeds inside NMR machines to boost resolution and sensitivity. These rotors will be combined with methods that enhance signal (Dynamic Nuclear Polarization) so scientists can see atomic-level structure and movement of amyloid-beta proteins using very small samples. The goal is to produce clearer, more detailed views of the protein aggregates involved in Alzheimer’s than current methods allow. Those clearer molecular pictures could help guide design of new diagnostics and drugs targeting these harmful protein assemblies.
Who could benefit from this research
Good fit: While this is a lab-focused project rather than a clinical trial, ideal contributors would be people with Alzheimer’s (or their families) who can donate brain tissue, cerebrospinal fluid, or other biospecimens for molecular analysis.
Not a fit: People seeking immediate changes to their clinical care or access to a new therapy are unlikely to benefit directly, since the grant develops laboratory tools rather than providing treatment.
Why it matters
Potential benefit: If successful, this work could let scientists see amyloid-beta structure and dynamics much more clearly, helping guide development of better Alzheimer’s tests and treatments.
How similar studies have performed: Related NMR and DNP approaches have improved structural studies previously, but using ultra-fast spinning diamond rotors at the proposed frequencies is novel and largely untested for amyloid-beta.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Gershenfeld, Neil — Massachusetts Institute of Technology
- Study coordinator: Gershenfeld, Neil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.